Mark Coleman

This profile gathers the share dealings of Mark Coleman in Axsome Therapeutics, Inc., where the filings describe the role as board member. In total, 23 filings cover trades dated from 12 May 2021 to 10 June 2026.

The open-market side counts 5 purchases for €207k alongside 9 sales for €8.2M. The totals exclude 1 filing filed without an amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 9 option exercises. So far in 2026, the count stands at no purchases and 5 sales.

The median purchase comes to €31k. Of 5 purchases, 1 formed part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

Most recently, on 10 June 2026, the filings show an option exercise in Axsome Therapeutics, Inc. The latest purchase dates back some time: it was published 404 days ago, on 9 September 2025. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.